window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Kim McLean Boericke

  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth

    Veristat, a global clinical research organization (CRO) and consultancy specializing [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cystic Fibrosis Foundation backs SpliSense with up to $13m to advance SPL84 Phase 2b study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Mabion revives MabionCD20 through rare disease collaboration with Oddifact
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Innovative Molecules adds Epstein-Barr virus antiviral programme to pipeline
    Categories: Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top